DERM
Journey Medical Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$106M
5Y Perf.-34.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DERM vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.69B
5Y Perf.-66.6%
DERM vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DERM | PRGO |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $106M | $1.69B |
| Revenue (TTM) | $56M | $4.18B |
| Net Income (TTM) | $-9M | $-1.82B |
| Gross Margin | 67.5% | 34.2% |
| Operating Margin | -12.2% | -4.1% |
| Forward P/E | 71.9x | 5.8x |
| Total Debt | $26M | $3.97B |
| Cash & Equiv. | $20M | $532M |
DERM vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DERM
PRGO
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Journey Medical Cor… (DERM) | 100 | 65.9 | -34.1% |
| Perrigo Company plc (PRGO) | 100 | 33.4 | -66.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DERM vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRGO leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Journey Medical Corporation is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
DERM
Journey Medical Corporation
The Long-Run Compounder
DERM is the clearest fit if your priority is long-term compounding.
- -45.2% 10Y total return vs PRGO's -76.8%
- -15.5% margin vs PRGO's -43.5%
- -19.8% vs PRGO's -45.6%
Best for: long-term compounding
PRGO
Perrigo Company plc
The Income Pick
PRGO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 10 yrs, beta 1.18, yield 9.4%
- Rev growth -2.8%, EPS growth -7.2%, 3Y rev CAGR -1.5%
- Lower volatility, beta 1.18, current ratio 2.76x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRGO | -2.8% revenue growth vs DERM's -29.1% |
| Value | PRGO | Lower P/E (5.8x vs 71.9x) |
| Quality / Margins | DERM | -15.5% margin vs PRGO's -43.5% |
| Stability / Safety | PRGO | Beta 1.18 vs DERM's 1.82 |
| Dividends | PRGO | 9.4% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | DERM | -19.8% vs PRGO's -45.6% |
| Efficiency (ROA) | DERM | -10.8% ROA vs PRGO's -19.8%, ROIC -56.8% vs 3.7% |
DERM vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
DERM vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDERMLAGGINGPRGO
PRGOPerrigo Company plc
1leads
DERMJourney Medical Corpo…
3leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DERM4/6
Valuation MetricsMultiples, price ratios, and targets
PRGO3/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DERM6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
DERM5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DERM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 74.1x DERM's $56M. DERM is the more profitable business, keeping -15.5% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, DERM holds the edge at +1.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $56M | $4.2B |
| EBITDAEarnings before interest/tax | -$3M | $58M |
| Net IncomeAfter-tax profit | -$9M | -$1.8B |
| Free Cash FlowCash after capex | -$3M | $108M |
| Gross MarginGross profit ÷ Revenue | +67.5% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -12.2% | -4.1% |
| Net MarginNet income ÷ Revenue | -15.5% | -43.5% |
| FCF MarginFCF ÷ Revenue | -4.8% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.0% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +5.9% | -56.4% |
DERM leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $106M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $112M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.24x | -1.19x |
| Forward P/EPrice ÷ next-FY EPS est. | 71.86x | 5.82x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.53x |
| Price / SalesMarket cap ÷ Revenue | 1.90x | 0.40x |
| Price / BookPrice ÷ Book value/share | 5.30x | 0.58x |
| Price / FCFMarket cap ÷ FCF | — | 11.63x |
PRGO leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
DERM leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
DERM delivers a -45.4% return on equity — every $100 of shareholder capital generates $-45 in annual profit, vs $-51 for PRGO. DERM carries lower financial leverage with a 1.28x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), PRGO scores 4/9 vs DERM's 2/9, reflecting mixed financial health.
| Metric | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | -45.4% | -50.7% |
| ROA (TTM)Return on assets | -10.8% | -19.8% |
| ROICReturn on invested capital | -56.8% | +3.7% |
| ROCEReturn on capital employed | -34.2% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 1.28x | 1.35x |
| Net DebtTotal debt minus cash | $5M | $3.4B |
| Cash & Equiv.Liquid assets | $20M | $532M |
| Total DebtShort + long-term debt | $26M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -1.52x | -7.20x |
DERM leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
DERM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DERM five years ago would be worth $5,484 today (with dividends reinvested), compared to $4,142 for PRGO. Over the past 12 months, DERM leads with a -19.8% total return vs PRGO's -45.6%. The 3-year compound annual growth rate (CAGR) favors DERM at 46.7% vs PRGO's -24.3% — a key indicator of consistent wealth creation.
| Metric | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | -30.1% | -9.6% |
| 1-Year ReturnPast 12 months | -19.8% | -45.6% |
| 3-Year ReturnCumulative with dividends | +215.8% | -56.6% |
| 5-Year ReturnCumulative with dividends | -45.2% | -58.6% |
| 10-Year ReturnCumulative with dividends | -45.2% | -76.8% |
| CAGR (3Y)Annualised 3-year return | +46.7% | -24.3% |
DERM leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DERM and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than DERM's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DERM currently trades 54.5% from its 52-week high vs PRGO's 43.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.82x | 1.18x |
| 52-Week HighHighest price in past year | $9.55 | $28.44 |
| 52-Week LowLowest price in past year | $4.31 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +54.5% | +43.1% |
| RSI (14)Momentum oscillator 0–100 | 43.4 | 53.7 |
| Avg Volume (50D)Average daily shares traded | 228K | 3.4M |
Evenly matched — DERM and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DERM as "Buy" and PRGO as "Hold". Consensus price targets imply 125.5% upside for DERM (target: $12) vs 63.1% for PRGO (target: $20). PRGO is the only dividend payer here at 9.38% yield — a key consideration for income-focused portfolios.
| Metric | DERMJourney Medical C… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $11.75 | $20.00 |
| # AnalystsCovering analysts | 3 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.4% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DERM leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics). 1 tied.
Best OverallJourney Medical Corporation (DERM)Leads 3 of 6 categories
Loading custom metrics...
DERM vs PRGO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is DERM or PRGO a better buy right now?
For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.
8% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DERM or PRGO?
Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -45.
2%, compared to -58. 6% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: DERM returned -45. 2% versus PRGO's -76. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DERM or PRGO?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus Journey Medical Corporation's 1. 82β — meaning DERM is approximately 54% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Journey Medical Corporation (DERM) carries a lower debt/equity ratio of 128% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — DERM or PRGO?
By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.
8% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Journey Medical Corporation grew EPS -242. 9% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DERM or PRGO?
Journey Medical Corporation (DERM) is the more profitable company, earning -26.
1% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps -26. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -24. 4% for DERM. At the gross margin level — before operating expenses — DERM leads at 62. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is DERM or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
8x forward P/E versus 71. 9x for Journey Medical Corporation — 66. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 125. 5% to $11. 75.
07Which pays a better dividend — DERM or PRGO?
In this comparison, PRGO (9.
4% yield) pays a dividend. DERM does not pay a meaningful dividend and should not be held primarily for income.
08Is DERM or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 4% yield). Journey Medical Corporation (DERM) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -76. 8%, DERM: -45. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between DERM and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: DERM is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while DERM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(DERM: 1.0% · PRGO: -7.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.